RE:Even better Nash news from Novo NordiskI see this as primarily a negative for THTX. They've wasted the possibility of playing in the NASH/MASH space as others race forward with potential drugs that could hit the market. At the same time, I guess if one of the big boys gets to market first, maybe a competitor will want something equivalent to compete for market share. Do we have something equivalent? I don't really know. Nothing ever works out for us. Still waiting on those TH-1902 results and an update on if Egrifta production issues were resolved.